SG11201405561RA - PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE - Google Patents
PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USEInfo
- Publication number
- SG11201405561RA SG11201405561RA SG11201405561RA SG11201405561RA SG11201405561RA SG 11201405561R A SG11201405561R A SG 11201405561RA SG 11201405561R A SG11201405561R A SG 11201405561RA SG 11201405561R A SG11201405561R A SG 11201405561RA SG 11201405561R A SG11201405561R A SG 11201405561RA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrazolo
- pyrimidine
- compositions
- methods
- based compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261608765P | 2012-03-09 | 2012-03-09 | |
| PCT/US2013/029056 WO2013134228A1 (en) | 2012-03-09 | 2013-03-05 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201405561RA true SG11201405561RA (en) | 2014-10-30 |
Family
ID=47892052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201405561RA SG11201405561RA (en) | 2012-03-09 | 2013-03-05 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US8946415B2 (ko) |
| EP (1) | EP2834243B1 (ko) |
| JP (1) | JP6418950B2 (ko) |
| KR (1) | KR101965025B1 (ko) |
| CN (1) | CN104302649B (ko) |
| AR (1) | AR090292A1 (ko) |
| AU (1) | AU2013230128B2 (ko) |
| BR (1) | BR112014022000A8 (ko) |
| CA (1) | CA2866143C (ko) |
| DK (1) | DK2834243T3 (ko) |
| ES (1) | ES2676224T3 (ko) |
| HK (1) | HK1201257A1 (ko) |
| HU (1) | HUE038786T2 (ko) |
| IL (1) | IL234486A (ko) |
| IN (1) | IN2014DN07384A (ko) |
| MX (1) | MX345830B (ko) |
| NZ (1) | NZ630721A (ko) |
| PL (1) | PL2834243T3 (ko) |
| PT (1) | PT2834243T (ko) |
| RU (1) | RU2014140735A (ko) |
| SG (1) | SG11201405561RA (ko) |
| TR (1) | TR201808280T4 (ko) |
| TW (1) | TW201341386A (ko) |
| UY (1) | UY34668A (ko) |
| WO (1) | WO2013134228A1 (ko) |
| ZA (1) | ZA201406149B (ko) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2834243T (pt) | 2012-03-09 | 2018-08-01 | Lexicon Pharmaceuticals Inc | Compostos à base de pirazolo[1,5-a]pirimidina, composições que os compreendem e métodos para a sua utilização |
| NZ630719A (en) | 2012-03-09 | 2017-01-27 | Lexicon Pharmaceuticals Inc | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof |
| US8901305B2 (en) | 2012-07-31 | 2014-12-02 | Bristol-Myers Squibb Company | Aryl lactam kinase inhibitors |
| JP2016509066A (ja) | 2013-02-22 | 2016-03-24 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | アダプター関連キナーゼ１（ａａｋ１）の阻害剤としての５ｈ−クロメノ［３，４−ｃ］ピリジン |
| TW201542550A (zh) * | 2013-09-06 | 2015-11-16 | Lexicon Pharmaceuticals Inc | 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法 |
| JP6473146B2 (ja) | 2013-10-11 | 2019-02-20 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ピロロトリアジンキナーゼ阻害剤 |
| RS65417B1 (sr) | 2014-01-24 | 2024-05-31 | Turning Point Therapeutics Inc | Diaril makrocikli kao modulatori protein kinaza |
| US9932320B2 (en) * | 2014-01-31 | 2018-04-03 | Bristol-Myers Squibb Company | Quinoline-based kinase inhibitors |
| TW201620911A (zh) * | 2014-03-17 | 2016-06-16 | 雷西肯製藥股份有限公司 | 銜接子關聯激酶１之抑制劑、包含其之組成物、及其使用方法 |
| EP3200797A1 (en) * | 2014-09-30 | 2017-08-09 | Bristol-Myers Squibb Company | Quinazoline-based kinase inhibitors |
| EP3233863B1 (en) * | 2014-12-15 | 2024-04-10 | CMG Pharmaceutical Co., Ltd. | Fused ring heteroaryl compounds and their use as trk inhibitors |
| EP3292124B1 (en) | 2015-04-10 | 2019-05-22 | Bristol-Myers Squibb Company | 6h-isochromeno[3,4-c]pyridines and benzo[c][1,7]naphthyridin-6-(5h)-ones as adaptor associated kinase 1 (aak1) inhibitors |
| WO2017004342A1 (en) | 2015-07-02 | 2017-01-05 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| CN108026108B (zh) | 2015-07-06 | 2021-06-22 | 特普医药公司 | 二芳基大环多晶型物 |
| DK3325488T3 (da) | 2015-07-21 | 2020-09-14 | Turning Point Therapeutics Inc | Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer |
| CN108349979B (zh) | 2015-11-02 | 2021-04-09 | 詹森药业有限公司 | [1,2,4]三唑并[1,5-a]嘧啶-7-基化合物 |
| SG11201900163PA (en) | 2016-07-28 | 2019-02-27 | Tp Therapeutics Inc | Macrocycle kinase inhibitors |
| ES2855032T3 (es) | 2016-11-02 | 2021-09-23 | Janssen Pharmaceutica Nv | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de PDE2 |
| CA3041412A1 (en) * | 2016-11-02 | 2018-05-11 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors |
| WO2018083101A1 (en) | 2016-11-02 | 2018-05-11 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| JP7216705B2 (ja) | 2017-07-28 | 2023-02-02 | ニンバス ラクシュミ， インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用方法 |
| IL271964B1 (en) | 2017-07-28 | 2024-08-01 | Turning Point Therapeutics Inc | Macrocyclic compounds and their uses |
| SI3728271T1 (sl) | 2017-12-19 | 2023-01-31 | Turning Point Therapeutics, Inc. | Makrociklične spojine za zdravljenje bolezni |
| JP7150356B2 (ja) * | 2017-12-22 | 2022-10-11 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | 置換ピラゾロ［１，５－ａ］ピリミジン化合物並びにその医薬組成物および使用 |
| CN111848622A (zh) | 2018-01-23 | 2020-10-30 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡唑并[1,5-a]嘧啶类的大环化合物 |
| US20220041588A1 (en) * | 2018-09-27 | 2022-02-10 | Fochon Pharmaceuticals, Ltd. | Substituted imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| JP2022502515A (ja) * | 2018-10-15 | 2022-01-11 | ニンバス ラクシュミ， インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| JP2023522689A (ja) | 2020-04-21 | 2023-05-31 | レクシコン ファーマシューティカルズ インコーポレイテッド | ＣｏＶ－２２９Ｅ又はＣｏＶ－ＯＣ４３コロナウイルス感染症の治療において使用される４－（３－（ピリジン－３－イル）ピラゾロ［１，５－ａ］ピリミジン－５－イル）ピペラジン |
| CN115484951A (zh) | 2020-04-21 | 2022-12-16 | 莱西肯医药有限公司 | 用于治疗病毒感染的aak1抑制剂 |
| US11478733B2 (en) | 2020-11-24 | 2022-10-25 | Caterpillar Inc. | Filter interlock with tabs mating with a pedestal or a housing |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| US6194410B1 (en) * | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
| JP4847275B2 (ja) * | 2005-10-21 | 2011-12-28 | 田辺三菱製薬株式会社 | ピラゾロ［１，５−ａ］ピリミジン化合物 |
| DE602007013441D1 (de) | 2006-09-29 | 2011-05-05 | Novartis Ag | Pyrazolopyrimidine als pi3k-lipidkinasehemmer |
| US20120058997A1 (en) * | 2006-11-06 | 2012-03-08 | Supergen, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| EA019507B1 (ru) * | 2008-05-13 | 2014-04-30 | Айрм Ллк | Конденсированные азотсодержащие гетероциклы и содержащие их композиции в качестве ингибиторов киназы |
| AR074052A1 (es) * | 2008-10-22 | 2010-12-22 | Array Biopharma Inc | Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa |
| AR077468A1 (es) * | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| WO2011029027A1 (en) | 2009-09-03 | 2011-03-10 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS |
| US8946237B2 (en) * | 2010-01-14 | 2015-02-03 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-A]pyrimidines as mark inhibitors |
| DK2734205T3 (en) * | 2011-07-21 | 2018-06-14 | Tolero Pharmaceuticals Inc | Heterocyclic Protein Kinase Inhibitors |
| NZ630719A (en) | 2012-03-09 | 2017-01-27 | Lexicon Pharmaceuticals Inc | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof |
| EP2822555B1 (en) * | 2012-03-09 | 2017-11-08 | Lexicon Pharmaceuticals, Inc. | Inhibition of adaptor associated kinase 1 for the treatment of pain |
| PT2834243T (pt) | 2012-03-09 | 2018-08-01 | Lexicon Pharmaceuticals Inc | Compostos à base de pirazolo[1,5-a]pirimidina, composições que os compreendem e métodos para a sua utilização |
| TW201620911A (zh) * | 2014-03-17 | 2016-06-16 | 雷西肯製藥股份有限公司 | 銜接子關聯激酶１之抑制劑、包含其之組成物、及其使用方法 |
-
2013
- 2013-03-05 PT PT137102505T patent/PT2834243T/pt unknown
- 2013-03-05 MX MX2014010589A patent/MX345830B/es active IP Right Grant
- 2013-03-05 US US13/785,355 patent/US8946415B2/en active Active
- 2013-03-05 ES ES13710250.5T patent/ES2676224T3/es active Active
- 2013-03-05 RU RU2014140735A patent/RU2014140735A/ru not_active Application Discontinuation
- 2013-03-05 CA CA2866143A patent/CA2866143C/en active Active
- 2013-03-05 IN IN7384DEN2014 patent/IN2014DN07384A/en unknown
- 2013-03-05 HU HUE13710250A patent/HUE038786T2/hu unknown
- 2013-03-05 KR KR1020147028071A patent/KR101965025B1/ko active IP Right Grant
- 2013-03-05 WO PCT/US2013/029056 patent/WO2013134228A1/en active Application Filing
- 2013-03-05 NZ NZ630721A patent/NZ630721A/en unknown
- 2013-03-05 EP EP13710250.5A patent/EP2834243B1/en active Active
- 2013-03-05 PL PL13710250T patent/PL2834243T3/pl unknown
- 2013-03-05 DK DK13710250.5T patent/DK2834243T3/en active
- 2013-03-05 AU AU2013230128A patent/AU2013230128B2/en active Active
- 2013-03-05 SG SG11201405561RA patent/SG11201405561RA/en unknown
- 2013-03-05 TR TR2018/08280T patent/TR201808280T4/tr unknown
- 2013-03-05 CN CN201380012483.0A patent/CN104302649B/zh active Active
- 2013-03-05 BR BR112014022000A patent/BR112014022000A8/pt not_active Application Discontinuation
- 2013-03-05 JP JP2014561024A patent/JP6418950B2/ja active Active
- 2013-03-08 TW TW102108283A patent/TW201341386A/zh unknown
- 2013-03-11 UY UY0001034668A patent/UY34668A/es not_active Application Discontinuation
- 2013-03-11 AR ARP130100765A patent/AR090292A1/es unknown
-
2014
- 2014-08-21 ZA ZA2014/06149A patent/ZA201406149B/en unknown
- 2014-09-07 IL IL234486A patent/IL234486A/en active IP Right Grant
- 2014-09-11 US US14/483,898 patent/US9403832B2/en active Active
-
2015
- 2015-02-13 HK HK15101651.1A patent/HK1201257A1/xx unknown
-
2016
- 2016-07-12 US US15/207,677 patent/US20170129896A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201406149B (en) | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | |
| HRP20181628T1 (hr) | Spojevi i postupci za njihovu upotrebu | |
| IL236075A (en) | History of imidazo [2,1 – b] pyridazine as kinase inhibitors, preparations containing them and their use History of imidazo [2,1 – b] pyridazine as kinase inhibitors, preparations containing them and their uses | |
| ZA201406148B (en) | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof | |
| HK1217658A1 (zh) | 基於吡唑並 嘧啶的化合物、包含其的組合物和其使用方法 | |
| IL237340A0 (en) | An anti-anxiety preparation, its formulation and method of using it | |
| HK1200449A1 (en) | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases bub1 | |
| IL240877A0 (en) | History of triazolo [5,4-d] pyrimidine, their preparation and pharmaceutical preparations containing them | |
| PL2768937T3 (pl) | Preparaty, ich zastosowanie jako środków do mycia naczyń lub do wytwarzania środków do mycia naczyń i ich wytwarzanie | |
| EP2931723A4 (en) | NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND LACTAMASE INHIBITORS | |
| HK1217659A1 (zh) | 基於咪唑並 噠嗪的化合物、包含它們的組合物及其使用方法 | |
| AP3751A (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines | |
| IL239447B (en) | Converted derivatives of tetrahydro[1,2,4]triazolo[alpha-3,4]pyrimidine-5-yl-benzyl and pharmaceutical preparations containing these derivatives | |
| AP3908A (en) | Novel 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo [4,5-B] pyridine compounds as modulators of C-met protein kinases | |
| PL2841549T3 (pl) | Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie | |
| PL2841548T3 (pl) | Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie | |
| HK1209740A1 (en) | Dioxino- and oxazin-[2,3-d]pyrimidine pi3k inhibitor compounds and methods of use --[23-d] pi3k | |
| HK1198365A1 (en) | Imidazopyridine compounds, compositions and methods of use | |
| ZA201500865B (en) | Process for the preparation of sitagliptin and intermediate compounds | |
| HK1205504A1 (en) | Substituted pyrazolo[1,5-a]pyridines, their preparation and use as medicaments [1,5-a] | |
| EP2809337A4 (en) | EFFECTORS OF SS-ARRESTINE AND COMPOSITIONS AND METHODS OF USE THEREOF | |
| EP2862571A4 (en) | CAMPTOTHECIN COMPOUND, AND ITS MANUFACTURE AND USE | |
| AP3582A (en) | (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases | |
| AU2012905317A0 (en) | Methods and Preparation and Use of Xanthorrhoeaceae Compositions | |
| GB201207064D0 (en) | Pharmaceutical compositions comprising 15-hetre and methods of using the same |